Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis by Iyasere, O et al.
O R I G I N A L A R T I C L E
Quality of life with conservative care compared with
assisted peritoneal dialysis and haemodialysis
Osasuyi Iyasere1, Edwina A. Brown2, Lina Johansson2, Andrew Davenport3,
Ken Farrington4, Alexander P. Maxwell5, Helen Collinson6, Stanley Fan7,
Ann-Marie Habib8, John Stoves9 and Graham Woodrow10
1John Walls Renal Unit, Leicester General Hospital, Leicester, UK, 2Imperial College Renal and Transplant cen-
tre, Hammersmith Hospital, London, UK, 3UCL Centre for Nephrology, Royal Free Hospital, London, UK, 4Lister
Hospital, Stevenage, UK, 5Centre for Public Health, Queen’s University Belfast, UK, 6Hull Royal Infirmary, Hull,
UK, 7Royal London Hospital, London, UK, 8St Helier Hospital, Carshalton, UK, 9Bradford Teaching Hospitals,
Bradford, UK and 10St James University Hospital, Leeds, UK
Correspondence and offprint requests to: Edwina A. Brown; E-mail: e.a.brown@imperial.ac.uk
ABSTRACT
Background. There is little information about quality of life (QoL) for patients with end-stage kidney disease (ESKD)
choosing conservative kidney management (CKM). The Frail and Elderly Patients on Dialysis (FEPOD) study demonstrated
that frailty was associated with poorer QoL outcomes with little difference between dialysis modalities [assisted peritoneal
dialysis (aPD) or haemodialysis (HD)]. We therefore extended the FEPOD study to include CKM patients with estimated
glomerular filtration rate 10 mL/min/1.73 m2 (i.e. individuals with ESKD otherwise likely to be managed with dialysis).
Methods. CKM patients were propensity matched to HD and aPD patients by age, gender, ethnicity, diabetes status and
index of deprivation. QoL outcomes measured were Short Form-12 (SF12), Hospital Anxiety and Depression Scale
depression score, symptom score, Illness Intrusiveness Rating Scale (IIRS) and Renal Treatment Satisfaction Questionnaire.
Frailty was assessed using the Clinical Frailty Scale. Generalized linear modelling was used to assess the impact of
treatment modality on QoL outcomes, adjusting for baseline characteristics.
Results. In total, 84 (28 CKM, 28 HD and 28 PD) patients were included. Median age for the cohort was 82 (79–88) years.
Compared with CKM, aPD was associated with higher SF12 physical component score (PCS) [Exp B (95% confidence
interval)¼1.20 (1.00–1.45), P<0.05] and lower symptom score [Exp B¼0.62 (0.43–0.90), P¼0.01]; depression score was lower
in HD compared with CKM [Exp B¼0.70 (0.52–0.92), P¼0.01]. Worsening frailty was associated with higher depression scores
[Exp B¼2.59 (1.45–4.62), P<0.01], IIRS [Exp B¼1.20 (1.12–1.28), P<0.01] and lower SF12 PCS [Exp B¼0.87 (0.83–0.93), P<0.01].
Conclusion. Treatment by dialysis, both with aPD and HD, improved some QoL measures. Overall, aPD was equal to or
slightly better than the other modalities in this elderly population. However, as in the primary FEPOD study, frailty was
associated with worse QoL measures irrespective of CKD modality. These findings highlight the need for an individualized
approach to the management of ESKD in older people.
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INTRODUCTION
Older, frailer individuals with end-stage kidney disease (ESKD)
are arguably more likely to choose conservative kidney man-
agement (CKM) over dialysis therapies if they are offered the
opportunity to participate in decision-making about their
care. CKM includes interventions to delay progression of kid-
ney disease and minimize complications as well as detailed
communication, shared decision-making, advance care
planning and psychologic and family support; it does not in-
clude dialysis [1]. Dialysis populations have changed markedly
with ageing of the population and following the expansion of
dialysis services allowing an exponential increase in the num-
ber of elderly patients now being treated by dialysis. Older
patients with ESKD have a high burden of ageing-related
health and social care problems, a high mortality rate and a
greater likelihood of developing the frailty syndrome requiring
social support within a few months of starting dialysis, what-
ever the modality [2–4]. Given this experience and observa-
tions that dialysis may not extend life in the very old, or those
with multiple comorbidities and poor physical function [5–7],
it is not surprising that a high percentage of the very old will
select conservative care for ESKD (no dialysis but active sup-
portive care) in healthcare cultures where this option is ac-
tively discussed, such as the UK [8] and Australia [9]. There is,
however, limited information about the quality of life (QoL)
and physical function of patients choosing conservative care
compared with haemodialysis (HD) or peritoneal dialysis (PD).
The two largest studies published come from the UK [10] and
Australia [11]. The first included 30 patients choosing conser-
vative care, but the groups were not age comparable and the
dialysis modality was predominantly HD. The Australian
study was larger, but again the groups were not age-matched,
and only half of patients completed QoL or symptom ques-
tionnaires. In both studies, the conservative care cohort
recruited patients choosing conservative care in pre-dialysis
clinics, when requirement for dialysis was distant. Neither
study mentions the estimated glomerular filtration rate (eGFR)
of conservative care patients when enrolled, so are subject to
lead-time bias.
The Frail and Elderly Patient Outcomes on Dialysis (FEPOD)
study is a multicentre observational study comparing the QoL
and physical function of older patients with ESKD and enrolled
129 patients receiving assisted peritoneal dialysis (aPD)
matched to 122 patients on HD requiring hospital-supplied
transport to hospital (incentre) dialysis facilities. This study
showed that the frailty score was associated with lower physi-
cal function and higher illness intrusiveness and symptom
scores; the only difference between the two dialysis modalities
was a higher treatment satisfaction score on aPD [12]. Given
these findings, we hypothesized that outcomes of QoL and
physical function would be similar between older patients on
dialysis and suitably matched patients receiving conservative
care for ESKD. We compared outcomes between patients who
had chosen conservative care with an eGFR 10 mL/min/
1.73 m2 (thus otherwise likely to require dialysis) and propensity
matched aPD and HD patients.
MATERIALS ANDMETHODS
Study design and recruitment
This was a multicentre cross-sectional study of patients receiv-
ing CKM, aPD and HD. CKM patients were recruited from 21
centres in the UK (England and Northern Ireland), between
December 2014 and June 2016. In this study, CKM patients were
defined as those receiving active non-dialysis care, with an
eGFR10 mL/min/1.73 m2. This was to exclude patients on a
supportive care pathway, who would opt for dialysis as renal
function deteriorates, but were not yet needing dialysis. Eligible
patients were 60 years old and had not been admitted to hos-
pital for 30 days.
The recruited CKM patients were propensity matched to
the original FEPOD cohort using the following criteria: age,
gender, ethnicity, presence of diabetes and index of depriva-
tion by post code [13]. The FEPOD cohort, which has been pre-
viously described [12], consists of older patients on HD and
aPD (n¼ 251). They had been recruited from the same renal
centres, between June 2011 and December 2013. They were
also over 60 years of age, had been on maintenance dialysis for
at least 3 months and with no hospital admissions for
30 days.
Patients who were deemed to have a life expectancy of
less than 6 months by the managing clinician were ex-
cluded from the study. Patients with dementia as well as
those unable to understand English were also excluded.
Centres were not asked to record how many patients they
reviewed and then deemed ineligible for inclusion into the
study.
aPD patients were defined as those who are unable to per-
form PD without the assistance of a paid healthcare worker or
family member. HD patients were defined as those requiring
hospital-funded transport (allocated after a mobility assess-
ment) to receive incentre dialysis.
Ethics and consent
The study was approved by the London–Fulham Research
Ethics Committee (REC Approval: 11/LO/1886). Eligible patients
were approached with a patient information sheet at least 24 h
prior to the study visit. All participants provided written in-
formed consent at the study visit.
Study visit
The study visit was conducted by local research teams at in-
dividual centres. Demographic and clinical characteristics
were collated at baseline from the medical records and dur-
ing the visit. The comorbidity burden was evaluated with the
Stoke–Davies comorbidity score. This prognostic score has
been shown to be predictive of survival [14] and is superior
to the Charlson Comorbidity index as a predictor of hospital-
ization in PD patients. A point is allocated for each of the fol-
lowing: ischaemic heart disease, peripheral vascular
disease, left ventricular dysfunction, diabetes, active malig-
nancy and systemic collagen vascular disease, and other sig-
nificant comorbidities. Higher scores indicate higher disease
burden.
Assessments of QoL and physical function were subse-
quently carried out, using questionnaires.
Assessments
Seven outcome measures were evaluated. These include the
Short Form-12 [SF12; Physical Component Summary scale (PCS)
and Mental Component Summary scale (MCS)], Hospital
Anxiety and Depression Scale (HADS), Palliative Outcomes
Scale-Symptoms (POS-S) (Renal), Illness Intrusiveness Rating
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Scale (IIRS), Renal Treatment Satisfaction Questionnaire (RTSQ)
and the Barthel score. Frailty was also assessed at baseline us-
ing the Clinical Frailty Scale (CFS), as an important confounder,
not as an outcome measure.
SF12 version 2. The SF12 is a self-assessment of physical and
mental health-related quality of life (HRQOL). Using patient
responses, two summary scores are calculated, namely, the
PCS and MCS. Higher scores are indicative of better HRQOL.
The SF12 has over 90% agreement with the widely used SF36.
It has also been shown to be a valid and reliable measure of
HRQOL in older people [15], with an associated lower comple-
tion burden.
HADS. This questionnaire screens for depression or anxiety
with scores ranging from 0 to 21. A depression score of 8 and
above is suggestive of possible depression [16]. The HADS scale
does not assess somatic symptoms of depression, which may
overlap with those of uraemia. It has been shown to have good
internal consistency in older people [17].
IIRS. This self-reporting tool assesses the extent to which the ill-
ness and/or treatment interferes with a patient’s life. The rating
scale evaluates intrusiveness in 13 life domains. It has been val-
idated in patients with ESKD [18], correlating with uraemic
symptoms, intercurrent non-renal illnesses, fatigue and diffi-
culties in daily activities. Scores range from 13 to 91, with higher
scores indicating more illness intrusion.
Symptoms. Symptoms were measured using the POS-S renal
scale. This is an adaptation of the POS, which was originally
developed for oncology patients to evaluate their palliative
care needs. For non-dialysis patients with advanced kidney
disease, it has been modified to include renal-specific
symptoms [19]. Scores range from 0 to 80, with higher scores
indicating increasing symptom burden. The POS-S renal score
has also been shown to be predictive of mortality in HD
patients [20].
Satisfaction with treatment. This was assessed using the RTSQ
[21]. This 11-item tool has been validated in HD, PD and
transplant patients. It assesses various aspects of treatment
satisfaction, including convenience, flexibility, freedom
afforded by treatment and impact on lifestyle. Scores range
from 0 to 66, with higher scores suggesting more treatment
satisfaction.
Barthel Index. This questionnaire evaluates performance in 10
activities of daily living [22]. Scores range from 0 to 100, with
lower scores suggesting increased dependence. It is, however,
sensitive to change over time.
CFS. This was used to measure frailty. Scores range from 1 to 7,
with higher scores corresponding to increasing levels of frailty.
It takes into consideration the presence of comorbidities as well
as dependence for activities of daily living. It has been shown to
be predictive of death or the need to be institutionalized, similar
to other established measures of frailty [23]. Frailty was mea-
sured as a potential confounder and not as an outcome
measure.
Statistical analysis
All analyses were carried out using the SPSS 22 package.
Continuous variables were expressed as median and interquar-
tile ranges, as they did not follow a normal distribution,
whereas categorical variables were expressed as percentages.
Unadjusted analysis. Clinical characteristics were compared be-
tween the CKM, aPD and HD cohorts. Statistical significance
tests were not used to compare demographic characteristics be-
tween the cohorts, which had been matched on demographics
and therefore do not constitute random samples from the re-
spective populations. Categorical variables were compared be-
tween the CKM, HD and aPD cohorts using Fisher’s exact tests.
Continuous variables were compared using the Kruskal–Wallis
test.
Regression analysis. Generalized linear modelling with gamma
error structure was used to evaluate the relationship between
QoL outcome measures and treatment modality (CKM versus
aPD; CKM versus HD). This is because the outcome measures
did not meet the assumption of normal distribution. A
generalized linear model was, therefore, generated for each of
the outcome variables of interest, including the SF12 PCS, SF12
MCS, HADS depression score, IIRS, POS-S renal score, RTSQ
score and Barthel score.
All models adjusted for age, gender, dialysis vintage, Stoke–
Davies comorbidity score and frailty score in addition to
treatment modality. These covariates were selected a priori as
potential confounders. Dialysis vintage was included as a con-
tinuous variable. The majority of CKM patients were not ex-
posed to dialysis. Therefore, the variable ‘dialysis vintage’
contained zero values. A fixed value of 0.001 was, therefore,
added to all values in the variable, before inclusion at the
modelling stage. Effect estimates were derived from the gamma
regression models. Each estimate represents the effect of each
covariate on the outcome measure after adjustment for all other
covariates in the model. Those effects with P< 0.05 were consid-
ered to be significant.
RESULTS
Only 28 CKM patients were recruited and, as shown in Table 1,
successfully propensity matched to aPD and HD patients on a
1:1:1 ratio, using aforementioned criteria. The cohort, therefore,
consisted of 84 patients, with a median age [CKM¼ 83, inter-
quartile range (IQR) 80–87 years; aPD¼ 81, IQR 79–88 years;
HD¼ 82, IQR 78–85 years] that was considerably higher than that
for the original FEPOD cohort (PD 76, IQR 70–81 years; HD 75, IQR
69–80 years) [12].
Table 1. Patient matching criteria
CKM (n¼ 28) aPD (n¼ 28) HD (n¼ 28)
Median age, IQR 83 (80–88) 81 (79–88) 82 (78–85)
Male gender (%) 50 50 43
Ethnicity (%)
White European 78.6 96.4 96.4
Asian 10.7 0.0 3.6
Afro Caribbean 10.7 3.6 0.0
Diabetes mellitus (%) 57 68 64.3
Median index of
deprivation (IQR)
22 (13–38) 17 (11–34) 19 (9–31)
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Table 2 shows the other demographic clinical and charac-
teristics for the cohort. The Stoke–Davies comorbidity score
of the CKM patients (median 1, IQR 0–2) was significantly
(P¼ 0.01) lower than in the aPD and HD patients (median 2,
IQR 1–3). Frailty, as defined by a frailty score 5, was com-
mon in all three groups with no significant difference be-
tween them (CKM 39.3%, aPD 60.7%, HD 39.3%; P¼ 0.18). A
higher proportion of CKM patients to be living alone (CKM
51.9%, aPD 42.9%, HD 30.9%), but this was not significant
(P¼ 0.07).
Study outcomes
Table 3 sets out the unadjusted outcomes of QoL for the CKM
patients compared with those on PD and HD. There were no sig-
nificant differences between the three groups for SF12 physical
and mental component scores, IIRS and symptom score. The
HADS depression score was lowest in the HD group (HD 5, IQR
3–7; aPD 7.5, IQR 5–10; CKM 7, IQR 5–10; P¼ 0.03), with a non-
significant trend towards a lower prevalence of possible depres-
sion (HADS depression score >7, HD—25%, aPD—53.6%, CKM—
46.4%; P¼ 0.07). There was also a trend towards lower RTSQ
score in the HD group (median 52, IQR 43.5–56) compared with
CKM (median 55.5, IQR 45.3–58.8) and PD (median 56, IQR 53–60;
P¼ 0.06).
Multivariate analysis using generalized linear models ad-
justed for age, gender, dialysis vintage, comorbidity score,
frailty and dialysis modality is shown in Table 4. The aPD
patients had higher SF12 PCS scores compared with CKM
patients [effect estimate PD versus CKM¼ 1.2 (1.00–1.45),
P¼ 0.05]. There was no significant difference between CKM and
HD patients. aPD patients also had significantly lower symptom
scores [effect estimates PD versus CKM¼ 0.62 (0.43–0.90),
P¼ 0.01] compared with CKM patients, with no difference be-
tween HD and CKM. The HD patients had lower HADS depres-
sion scores [effect estimates HD versus CKM¼ 0.70 (0.52–0.92),
P¼ 0.01] compared with CKM patients. Frailty was associated
with lower PCS on SF12 [effect estimate ¼ 0.87 (0.83–0.93),
P< 0.01], higher depression score [Effect estimate¼ 2.59 (1.45–
4.62), P< 0.01] and illness intrusiveness [effect estimate¼ 1.20
(1.12–1.28), P< 0.01]. There was also a trend towards lower
RTSQ scores in the HD cohort [effect estimate¼ 0.90 (0.80–
1.00), P¼ 0.06] compared with CKM patients, with no differ-
ence between aPD and CKM patients. Treatment modality was
not associated with any differences in SF12 MCS and IIRS
scores.
DISCUSSION
The aim of this study was to compare the QoL and physical
function of patients on a conservative care pathway for ESRD
compared with those receiving aPD and incentre HD. Patients
were defined as being on a conservative care pathway at the
point after they have engaged in an active decision-making pro-
cess about the options for management of ESKD and have opted
not to have dialysis. The timing of such discussions is at the dis-
cretion of nephrology healthcare teams. Indeed, in two recent
retrospective studies comparing survival of those choosing con-
servative care and those starting on dialysis [6, 7], analyses
were undertaken when patients still had an eGFR of 20 mL/min/
1.73 m2, that is, at a time point when dialysis is not required;
many of the deaths would therefore be related to comorbid con-
ditions and not to ESKD per se. In our study, all the patients on
the conservative care pathway had an eGFR of 10 mL/min/
1.73 m2, so would likely to have started dialysis if that had been
their wish.
The patients in the conservative care group, as expected,
were very old with a median age of 83 years. Surprisingly, they
Table 2. Clinical characteristics
CKM aPD HD
P(n¼ 28) (n¼ 28) (n¼ 28)
Median Stoke–Davies
comorbidity score, IQR
1 (0–2) 2 (1–3) 2 (1–3) 0.01
Comorbidity (%)
Ischaemic heart disease 25.9 28.6 42.9 0.32
Left ventricular dysfunction 7.1 21.4 25.0 0.18
Peripheral vascular disease 3.6 28.6 21.4 0.04
Malignancy 25.0 10.7 14.3 0.33
Systemic collagen
Vascular disorder
0.0 7.1 3.6 0.36
Median frailty score (IQR) 4 (3–5) 5(4–5) 4 (3–5) 0.21
Frailty score 5 (%) 39.3 60.7 39.3 0.18
Dialysis vintage (%)
No dialysis 96.4 0.0 0.0
1–12 months 0.0 32.1 10.7
13–60 months 0.0 53.6 89.3
60–120 months 0.0 10.7 0.0
>120 months 3.6 3.6 0.0
Fall in preceding 6 months (%) 25.9 28 48.1 0.17
Social network
Residence (%)
Own home 85.2 89.3 78.6 0.36
Warden-controlled flat 14.8 10.7 14.3
Nursing home 0.0 0.0 7.1
Lives alone (%) 51.9 42.9 30.8 0.07
Help from friend/family (%) 36.1 32.8 31.1 0.66
Paid help received (%) 37 33.3 56 0.21
Table 3. Univariate comparison: outcomes of QoL and physical function
Outcome measures CKM aPD HD P
SF-12 PCSa, median (IQR) 28.9 (19.8–33.3) 30.8 (20.9–33.1) 29.2 (23.4–34.7) 0.62
SF-12 MCSa, median (IQR) 46.3 (38.8–55.2) 50.2 (38.3–61.6) 49.9 (40.4–57.9) 0.68
HADS depression score, median (IQR) 7 (5–9) 7.5 (5–10) 5 (3–7) 0.03
HADS >7 (%) 46.4 53.6 25 0.07
Illness Intrusiveness Rating Scale, median (IQR) 30.5 (21.5–31.8) 32.0 (20.8–41.8) 31.0 (21–38) 0.79
Renal Treatment Satisfaction Questionnairea, median (IQR) 55.5 (45.3–58.8) 56 (53–60) 52 (43.5–56) 0.06
Symptom score, median (IQR) 20 (13–27) 16 (9–21) 22 (11–26.5) 0.10
aA higher score indicates better quality of life.
MCS, mental component summary; PCS, physical component summary; SF-12, short form 12.
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had a lower comorbidity score than the dialysis cohorts, but
this is similar to a recent Canadian study in which patients
choosing conservative care for ESKD had fewer comorbidities
than those on dialysis [24]. There was a non-significant trend
for conservative care patients to be living on their own; this
may have influenced their decision to choose CKM and not to
have dialysis.
A major strength of our study is that each CKM patient was
matched to both a patient managed by aPD and with a patient
receiving incentre HD requiring hospital-supplied transport. In
the UK, although dialysis treatments and medications are free
of charge, transport to and from dialysis centres is restricted to
only those with impaired mobility. There was no difference in
length of time on dialysis comparing aPD and HD patients; it
was not possible to record how long the CKM patients had had
an eGFR <10 mL/min/1.73 m2. In the multivariate analysis, CKM
patients were compared with those on aPD and those on HD in-
dependently. Compared with those managed by aPD, CKM
patients had a lower SF12 PCS and a higher symptom score.
CKM patients also had a higher depression score compared with
those on HD, though it needs to be pointed out that the HD self-
reported depression scores in our study were lower than most
previously published in the literature. There was a non-
significant trend for RTSQ scores to be lower for patients on HD
compared with those on CKM. The other key factor related to
outcomes was frailty, which was associated with lower SF12
PCS, higher depression score and higher illness intrusiveness,
irrespective of modality choice.
Only one study has previously directly compared patients
choosing conservative care for ESKD with those receiving PD
[25]; this study was conducted in Hong Kong, which has a ‘PD
first’ policy resulting in an unselected PD population.
Baseline renal function was similar in the conservative care
and PD populations (mean eGFR 6.8 and 6.3 mL/min/1.73 m2,
respectively). In this retrospective observational study, the
primary outcome was patient survival and there were no
measures of QoL. Survival with conservative care was similar
to that of PD patients who required assistance for activities
of daily living, comparable to studies comparing survival of
conservative care for ESKD to patients predominantly man-
aged by HD [5–7].
Symptom burden has been reported to be high for ESKD
patients following conservative care pathways [26]. There are
however, very few data about QoL for patients on conservative
care pathways compared with those receiving dialysis. The
first report related to a small cohort of 11 patients from Verona
[27]; QoL was measured in only six patients on CKM who were
still alive at the time of the study; similar to our study, these
CKM patients had a lower PCS on SF36 compared with five
patients on HD and mental component scores were similar. In
the study of Da Silva-Gane et al. [10], 30 patients choosing con-
servative care for ESKD were compared with those having dial-
ysis, predominantly HD. In this study, conservative care
patients were older, had more comorbidities and had poorer
physical health than those on dialysis; life satisfaction scores
were similar at baseline and remained stable in those receiving
CKM but decreased in the dialysis cohort. A more recent
Australian study included 122 ESKD patients choosing conser-
vative care, but only half completed QoL questionnaires [11];
they were also considerably older than the patients in the com-
parison dialysis cohort. Neither of these latter two studies pro-
vided the eGFR of the patients in the conservative care groups.
A study from Singapore, where all patients have to pay for dial-
ysis treatments, suggested that QoL was similar for older and
multiply comorbid patients on conservative care compared
with those on dialysis, but the burden of kidney disease is
higher in the dialysis group [28]. However, this study could be
confounded by social and financial differences between the
groups.
Our study has some notable limitations. The number of
patients receiving CKM who were recruited to the study was
lower than anticipated and may have introduced a selection
bias. Most of the UK centres taking part in the study had specific
conservative care clinics, but few centres could identify patients
with eGFR of 10 mL/min/1.73 m2. Discussions about dialysis or
conservative care are usually undertaken at higher eGFR levels,
so many patients were not therefore eligible for the study. Some
patients with sufficiently low eGFR were deemed by their ne-
phrologist to be too unwell to be included in the study or did not
Table 4. Multivariate analysis using generalized linear models
Outcome variable Predictors Exp B (95% CI) P
SF12 PCS Age 1.01 (0.99–1.03) 0.10
Female gender 0.89 (0.78–1.02) 0.10
Dialysis vintage 1.00 (1.00–1.00) 0.52
Stoke comorbidity score 1.02 (0.96–1.07) 0.57
Frailty score 0.87 (0.83–0.93) <0.01
aPD versus CKM 1.20 (1.00–1.45) 0.05
HD versus CKM 1.08 (0.89–1.29) 0.45
SF12 MCS Age 1.00 (0.99–1.01) 0.94
Female gender 0.91 (0.81–1.03) 0.14
Dialysis vintage 1.00 (0.99–1.00) 0.97
Stoke comorbidity score 0.99 (0.94–1.04) 0.72
Frailty score 0.95 (0.91–1.00) 0.07
aPD versus CKM 1.07 (0.90–1.27) 0.44
HD versus CKM 1.03 (0.87–1.22) 0.71
HADS depression
score
Age 0.94 (0.81–1.10) 0.44
Female gender 5.82 (1.52–22.3) 0.01
Dialysis vintage 1.03 (0.99–1.06) 0.11
Stoke comorbidity score 1.25 (0.72–2.19) 0.43
Frailty score 2.59 (1.45–4.62) <0.01
aPD versus CKM 0.86 (0.86–1.12) 0.24
HD versus CKM 0.70 (0.52–0.92) 0.01
IIRS Age 0.98 (0.96–0.99) 0.04
Female gender 1.06 (0.90–1.24) 0.50
Dialysis vintage 1.00 (0.99–1.00) 0.97
Stoke comorbidity score 0.93 (0.87–0.99) 0.03
Frailty score 1.20 (1.12–1.28) <0.01
aPD versus CKM 1.11 (0.86–1.42) 0.42
HD versus CKM 1.17 (0.93–1.48) 0.19
Symptom score Age 1.00 (0.97–1.02) 0.70
Female gender 1.12 (0.90–1.40) 0.32
Dialysis vintage 1.00 (0.99–1.01) 0.45
Stoke comorbidity score 1.03 (0.92–1.14) 0.61
Frailty score 1.07 (0.97–1.19) 0.17
aPD versus CKM 0.62 (0.43–0.90) 0.01
HD versus CKM 0.90 (0.66–1.21) 0.48
RTSQ Age 1.00 (0.99–1.01) 0.75
Female gender 0.94 (0.88–1.02) 0.12
Dialysis vintage 1.00 (1.00–1.00) 0.11
Stoke comorbidity score 0.99 (0.96–1.03) 0.68
Frailty score 0.99 (0.96–1.03) 0.47
aPD versus CKM 0.98 (0.88–1.10) 0.75
HD versus CKM 0.90 (0.80–1.00) 0.06
All adjusted for age, gender, dialysis vintage, Stoke-Davies comorbidity score,
frailty and dialysis modality.
CI, confidence interval. Bold value indicates statistically significant.
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give consent. This, plus the observation that a higher proportion
of CKM patients lived on their own, could explain the surprising
observation of a lower comorbidity score and lower prevalence of
peripheral vascular disease and left ventricular dysfunction com-
pared with patients established on dialysis. The bias, therefore, is
that the CKM patients in the study were fitter than otherwise to
be expected; this makes the finding of some worse aspects of QoL
compared with those on dialysis even more striking.
Previous studies have reported an initial high mortality rate
when elderly patients first start dialysis, particularly HD, and as
we only recruited patients after 90 days of dialysis, this may
have the potential to introduce a survivor bias. A further poten-
tial bias is the apparently low prevalence of self-reported de-
pression in the HD patients selected by the matching process.
The study design, and therefore accompanying ethical approval,
did not permit extracting information about those patients who
did not provide study consent. The study was also of cross-
sectional design, which limits results to associations and not
causality. In addition, although the largest study to date, our
study may have been underpowered as a result of the relatively
small sample size. Finally, our study findings need to be inter-
preted in light of the UK healthcare system, which provides uni-
versal coverage. QoL outcomes will vary depending on financial
burden of healthcare and extent of social and family support re-
lated to cultural beliefs and customs.
In summary, this study shows that for patients with ESKD
whose renal function has fallen to a level when dialysis is likely
to be considered (eGFR10 mL/min/1.73 m2), many aspects of
QoL (mental component score and illness intrusiveness) will be
similar whether managed conservatively or with dialysis.
However, physical QoL appears to be higher and symptom score
lower for those opting for aPD compared with conservative care.
Treatment satisfaction was similar for both conservative care
and aPD, but probably lower for HD. Shared decision-making is
a key component of comprehensive conservative care of ESKD
[18]. This study does provide information that can be provided
to older and/or frail patients, and their families, who are making
decisions whether to have conservative care for ESKD or dialy-
sis—and which dialysis modality to choose.
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